Company intelligence / Profile preview

Gensignia Life Sciences

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Developed a blood-based microRNA assay for early lung cancer detection to reduce LDCT false positives, with 87% sensitivity, 99% NPV, validated in 939-patient study published in JCO 2014; planned US launch in 2014 but no recent activity.

Therapeutic areas: Oncology
Industry: Molecular Diagnostics

Partnerships

Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan

Beyond the preview

Go deeper on Gensignia Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gensignia Life Sciences.

Explore the full profile